Bioequivalence Study of Carvedilol 12.5mg Tablets Under Fed Conditions
Status:
Completed
Trial end date:
2003-12-01
Target enrollment:
Participant gender:
Summary
The objective of this study was to compare the single-dose oral bioavailability of Carvedilol
12.5 mg tablets of Ranbaxy Laboratories with Coreg 12.5 mg tablets of Glaxosmithkline in
healthy, adult, human subjects under fed conditions.